Showing papers in "Value in Health in 1999"

TL;DR: Some of the unique challenges of HRQL research are outlined and recommendations for assuring that claims are based on the results of rigorous studies designed and conducted according to accepted scientific principles and practices are made.

TL;DR: A large number of the questioned people believe that current policies and practices in the field of health policy and management need to be changed to facilitate informed and efficient use of medical technology.

TL;DR: A brief, sensitive outcome measure designed to have wide application across psychiatric and psychological treatments and populations, suggesting the scale has excellent potential to be broadly responsive to a variety of treatment effects.

TL;DR: The findings suggest that there are multiple factors that influence an individual's assessment of their HRQL and that these factors need to be considered in the management and treatment of culturally diverse cancer patients.

TL;DR: In all cases, extended thromboprophylaxis with enoxaparin was associated with improved survival and life-years gained and resulted in increased costs for health care services.

TL;DR: Prolonged prophylaxis with the low molecular weight heparin enoxaparin after elective hip arthroplasty is cost-effective provided that at least 50% of the patients can administer the subcutaneous injections themselves.

TL;DR: Increasing the detection of hypertension and improving adherence to current guidelines might prevent a considerable proportion of the incident strokes among hypertensives.

TL;DR: To estimate costs and outcomes, existing data are frequently insufficient to allow optimal healthcare decision-making and modeling practice incorporates the best available evidence from all possible sources into a set of explicit parameters.

TL;DR: Most of the cost-savings associated with fluoxetine use were associated with the increased likelihood of completed therapy, and the total costs of treating depression in the ambulatory setting were found to vary widely across alternative antidepressants.

TL;DR: Retrospective databases can be useful tools for health economic evaluations because they offer large populations using real-world information within rapid and realistic treatment periods, and can an-swer questions related to cost-effectiveness.

TL;DR: An econometric method that is unbiased in the presence of endogeneity and therefore broadens the potential for use of retrospective data in the estimation of treatment effects is proposed, and is also designed to accommodate nonlinearity in the relationship between the treatment variable and the outcome.

TL;DR: Drug claim renewal rates were low for both oxybutynin and flavoxate, suggesting that money spent on these therapies provides an inadequate clinical return on investment since the majority of patients discontinue treatment prematurely.

TL;DR: Inhaled corticosteroids was the only class of medications that was found to decrease significantly after the implementation of the drug insurance plan, and neuroleptics and anticonvulsants suffered a non significant decrease.

TL;DR: This study aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the safe and effective use of EMTs in clinical practice.

TL;DR: This report is a summary of key issues in consensus development regarding the conduct and reporting of health economic research in the European context, presented and discussed at the ISPOR Inaugural European Conference in Cologne, Germany, December 1998.

TL;DR: There was no difference in rates of hospitalization at the levels of medication noncompliance observed in this population, and hospitalization could be attributed to other causes such as severity of illness and existence of other comorbid conditions.

TL;DR: Patients who began treatment with sertraline as opposed to fluoxetine had fewer days of antidepressant therapy and were more likely to receive average doses greater than the minimum recommended during therapy.

TL;DR: Until population-based data on managed care enrollees becomes available, and until such data can be linked to utilization and health outcomes information, investigations into the quality of services provided by MCOs compared to FFS plans cannot be definitive.

TL;DR: Over the long term, it is recommended that effort be directed towards better consensus and a greater degree of standardization of defini-tions and methodologies for assessing health eco-nomic questions through clinical studies.

TL;DR: The simulation analysis showed that the simultaneous modeling approach is significantly more unbiased and efficient in predicting the true cost-effectiveness ratio, compared to the average-effect model.

TL;DR: The results indicate that the PDI does not capture a unidimensional concept, and further validation is necessary to estimate the sensitivity to change.